c-Myc

c-Myc
Name	c-Myc
Organism	Homo sapiens
Band	24.21
EntrezGene	4609
HGNC	7553
OMIM	190080
RefSeq	NM_002467
UniProt	P01106

c-Myc. It is a master transcription factor encoded by the MYC gene, a member of the Myc family of proto-oncogenes. This protein is a central regulator of numerous cellular processes, including cell cycle progression, apoptosis, cellular metabolism, and ribosome biogenesis. Its expression is tightly controlled in normal cells, but dysregulation is a hallmark of many human cancers, making it a critical focus in oncology and molecular biology research.

Structure and function

The c-Myc protein contains several key domains essential for its activity, including a basic helix-loop-helix (bHLH) motif and a leucine zipper (LZ) region, which facilitate dimerization with its partner protein Max. This heterodimer binds to specific sequences known as E-box elements in the promoters of target genes. Through this mechanism, c-Myc activates the transcription of a vast network of genes involved in growth and proliferation. It also functions as a transcriptional repressor for certain genes, often through interactions with proteins like Miz-1. Its broad functional repertoire is enabled by its ability to modulate global chromatin structure and recruit complexes like the TRRAP-GCN5 acetyltransferase complex.

Role in cancer

Dysregulation of c-Myc is one of the most common events in human malignancies, contributing to the pathogenesis of a wide array of cancers, including Burkitt's lymphoma, neuroblastoma, and breast cancer. This often occurs via chromosomal translocation, such as the classic translocation between chromosome 8 and chromosome 14 seen in Burkitt's lymphoma, or through gene amplification. Constitutive c-Myc expression drives uncontrolled cell proliferation, inhibits cellular differentiation, and promotes genomic instability. It also reprograms cellular metabolism to support rapid growth, a phenomenon often referred to as the Warburg effect. The Myc family member N-Myc plays a similar oncogenic role in tumors like neuroblastoma.

Regulation

The expression and activity of c-Myc are controlled at multiple levels. Transcriptionally, it is regulated by numerous signal transduction pathways, including the Wnt and Hedgehog pathways. Key upstream regulators include growth factor receptors and transcription factors like β-catenin. Post-transcriptionally, its mRNA stability is modulated by RNA-binding proteins. The c-Myc protein itself is highly unstable, with a short half-life controlled by ubiquitin-mediated proteasomal degradation, a process involving the SCF complex and the F-box protein FBXW7. Phosphorylation by kinases such as GSK-3 can target it for degradation.

Interactions

c-Myc's function is mediated through a complex network of protein-protein interactions. Its primary and essential partner is Max, with which it forms a heterodimer to bind DNA. In contrast, dimerization with Mad family proteins like Mxd1 can antagonize its function. It interacts with transcriptional co-activators like TRRAP and TIP60 to modify histone acetylation. For repression, it partners with Miz-1 and recruits DNA methyltransferase complexes. Its role in metabolism involves interactions with factors like HIF-1α. The PI3K/AKT/mTOR pathway also intersects with c-Myc activity to coordinate growth signals.

Clinical significance

Given its pivotal role in oncogenesis, c-Myc is a major target for cancer therapy, though directly inhibiting transcription factors has proven challenging. Strategies include disrupting the c-Myc/Max dimerization with small molecules, using BET bromodomain inhibitors like JQ1 to downregulate its transcription, and targeting downstream metabolic pathways it controls. Its expression levels can serve as a prognostic marker in cancers like diffuse large B-cell lymphoma. Research into synthetic lethality has identified vulnerabilities in c-Myc-driven cancers, such as dependence on the CHK1 kinase. The National Cancer Institute supports numerous studies in this area.

Research history

The c-Myc oncogene was first identified through its homology to the transforming gene of the avian myelocytomatosis virus (MC29). Pioneering work by J. Michael Bishop and Harold E. Varmus on retroviral oncogenes, for which they received the Nobel Prize in Physiology or Medicine, laid the groundwork for understanding proto-oncogenes like MYC. The discovery of its chromosomal translocation in Burkitt's lymphoma by researchers including George Klein linked it directly to human cancer. Landmark studies from laboratories like those of Robert N. Eisenman and Bruno Amati have elucidated its function as a transcription factor and its complex regulatory network, solidifying its status as a central node in cell biology and cancer research.

Category:Transcription factors Category:Oncogenes Category:Human proteins